← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cancer Targeted Technology, Llc
Woodinville, WA
$13,636,102
Total funding
7
Grants
Funding over time
peak $2.9M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,636,102 · 7
By mechanism
R44$11,036,102 · 5
N43$2,300,000 · 1
R43$300,000 · 1
Investigators at Cancer Targeted Technology, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
IGF::OT::IGF DEVELOPMENT OF AN INNOVATIVE PSMA-TARGETED RADIONUCLIDE THERAPY FOR PROSTATE CANCER. PERIOD OF PERFORMANCE: 09/30/2015 - 02/28/2018.$2,000,000
N43 · FY2016 · CA
Development of an Innovative PSMA-Targeted Small Molecule Prodrug for Prostate Cancer$1,999,998
R44 · FY2025 · CA
Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer$1,441,580
R44 · FY2020 · CA
Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer$1,375,908
R44 · FY2019 · CA
Development of a novel PET imaging agent for prostate cancer$1,145,108
R44 · FY2011 · CA
Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic$1,076,087
R44 · FY2015 · CA
Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy$1,000,002
R44 · FY2021 · CA
Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy$999,998
R44 · FY2022 · CA
Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic$923,913
R44 · FY2016 · CA
Development of an Innovative PSMA-Targeted Small Molecule Prodrug for Prostate Cancer$400,000
R44 · FY2024 · CA
Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer$365,867
R44 · FY2021 · CA
Development of a novel PET imaging agent for prostate cancer$307,641
R44 · FY2010 · CA
Development of a PSMA-Targeted Small-Molecule Drug Conjugate for Prostate Cancer$300,000
R43 · FY2018 · CA
Development of an Innovative PSMA-targeted Radionuclide Therapy for Prostate Cancer$300,000
N43 · FY2015 · CA